Status:
COMPLETED
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
Lead Sponsor:
Ipsen
Conditions:
Memory Disorders, Age-Related
Retention Disorders, Cognitive
Eligibility:
All Genders
70+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.
Eligibility Criteria
Inclusion
- Spontaneously reporting a memory complaint
- Short anxiety battery test \< 6, (only if patient screened at GP site)
- Geriatric depression scale \< 15
- Mini-mental state (MMS) \> 25 in GP's office (in hospital site MMS is done as complementary scale)
Exclusion
- Objective memory impairment
- Clinician rated dementia staging system \> 0.5
- Mini-mental state \< 25
- Dementia, past history of seizures, Parkinson disease
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
2878 Patients enrolled
Trial Details
Trial ID
NCT00276510
Start Date
February 1 2002
End Date
November 1 2009
Last Update
January 15 2019
Active Locations (698)
Enter a location and click search to find clinical trials sorted by distance.
1
1 rue de l'Orient
Agde, France, 34300
2
3 Avenue de Marlioz
Aix-les-Bains, France, 73100
3
3 rue Auguste Delaune
Alès, France, 30100
4
17 rue du Cardinal Georges d'Amboise
Amboise, France, 37400